Clinical Trial Update: Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data

View source ↗

Summary

This study updates care pathways and costs for patients treated with CAR T-cell therapies using SNDS data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CAR-T cell therapy

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia (ALL) | Status: COMPLETED